**AA-02** THE EXPRESSION OF AUTOANTIBODIES TO MITOCHONDRIA IN THE BLOOD OF PATIENTS WITH SLE

1David S Pisetsky, 1Diane M Spencer, 2Farzana Mobarez, 2Enrico Fuzzi, 2Élisabet Sverengsson. 1Department of Medicine, Duke University Medical Center; Medical Research Service, Durham VA Medical Center, Durham, North Carolina USA; 2Unit of Rheumatology, Department of Medicine, Sahlgrenska University Hospital, Göteborg, Sweden

**Background** Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by the expression of antibodies to extracellular vesicles (EVs). These vesicles can arise from dead and dying cells and display nuclear and cytoplasmic molecules. Since EV preparations contain mitochondria, we performed experiments to test directly the binding of SLE antibodies to mitochondria.

**Methods** Mitochondria were prepared from mouse liver and immobilized on microtiter plates pre-coated with poly-l-lysine at 0.5 μg/ml. Bound antibodies were detected using a peroxidase-conjugated anti-IgG reagent. To determine whether DNA contributed to the antigenicity of the mitochondria, the ability of DNA to inhibit binding was tested. The binding of sera from 211 SLE patients who met 1982 ACR criteria for classification was determined by ELISA and results compared with an ELISA for M2 antimitochondrial antibodies (AMA).

**Results** Using an ELISA assay with immobilized mitochondria, 60.2% of SLE sera showed positive responses defined as greater than two standard deviations above the mean of control sera. Samples were also analyzed using a commercial AMA ELISA (Euroimmun US, Morris Plains, New Jersey) for IgG antibodies to the M2 antigen. With this kit, 5.7% of the SLE samples tested positive. To determine the relationship of antibodies to anti-DNA, the ability of calf thymus (CT) DNA to inhibit binding to mitochondria was investigated for a subset of samples. In the ELISA, CT DNA at 50 μg/ml inhibited binding for 7 of 8 SLE plasmas, with inhibition ranging from 7.76%–59.3%.

**Conclusion** These results indicate that blood of patients with SLE contain antibodies to mitochondria. Among these antibodies, some may react to DNA as shown by the ability of soluble DNA to inhibit ELISA binding. While binding mitochondria, these antibodies differ from AMA found in primary biliary cholangitis since few reacted in the ELISA for M2 AMA. Since studies using flow cytometry have demonstrated that IgG positive EVs in the blood of patients contain mitochondria as shown by MitoTracker Deep Red, these results suggest that, like nuclei, mitochondria may be a subcellular organelle that can display autoantigenic determinants to form immune complexes in SLE.

**AA-03** NEURONAL-SURFACE P-ANTIGEN (NSPA), TARGET OF ANTI-RIBOSOMAL P AUTOANTIBODIES, IS EXPRESSED IN PROXIMAL TUBULE EPITHELIAL CELLS (PTEC): POTENTIAL ROLE IN LUPUS NEPHRITIS

1Marcela Bravo-Zehnder, 1Patricia Gajardo, 1Daniela Valenzuela, 1Tomás Toledo, 1Angel Jurado, 1Fabíán Segovia, 1García López, 1Carlos Vio, 1Loreto Massardo, 1Alfonso González. 1Center for Cell Biology and Biomedicine (CEBICEM), Faculty of Medicine and Science, Universidad San Sebastián, Santiago, Chile; 2Center for Aging and Regeneration (CARE), Faculty of Biological Science, Pontificia Universidad Católica de Chile, Santiago, Chile

**Background** Patients with systemic lupus erythematosus (SLE) and anti-ribosomal P (anti-P) antibodies may present lupus psychosis, cognitive impairment and lupus nephritis (LN). Our group provided a molecular mechanism to explain the neuronal alterations in SLE identifying the neuronal-surface P-antigen (NSPA) as an anti-P target involved in the regulation of synaptic glutamatergic transmission (Bravo-Zehnder et al. *A and R* 2015; Segovia-Miranda et al. *A and R* 2015). There is evidence suggesting that anti-P- and anti-dsDNA antibodies have the potential to perturb the function of renal cells in addition to complement activation. The mechanism of anti-P association with lupus nephritis remains unclear. It is possible that direct anti-P interaction with cell surface components activates intracellular signalling pathways resulting in renal cell damage. As a first approximation to this hypothesis we study whether and where NSPA is expressed in the kidney.

**Methods** NSPA expression was assessed by RT-PCR, immunoblot and anti-NSPA immunohistochemistry in C57WT mice, β-galactosidase (β-gal) histochemistry staining in transgenic mice bearing a LacZ gene under the promoter of NSPA gene and anti-P staining in the surface of primary cultures of PTEC and the human kidney cell line HK2. NSPA polarized distribution was studied in Madin-Darby canine kidney (MDCK) cells transfected with NSPA-GFP expression plasmid. The pathogenic potential of anti-P antibodies was analyzed by immunizing C57WT and NSPAKO mice with recombinant P0 ribosomal bearing (P0*) or not the P epitope (P0*) and testing anti-P and anti-dsDNA presence, proteinuria and renal pathology by histochemistry and electron microscopy.

**Results** NSPA is expressed in PTEC cells and display a mainly apical distribution in *vivo* and in *vitro*, including the transfected MDCK cells. Both P0* and P0* generated high levels of anti-P antibodies and some mice also developed anti-dsDNA antibodies. Mice presented mild proteinuria at 6 months of immunization. C57WT and NSPAKO mice immunized with either P0* or P0* also displayed perivenular lymphocytic infiltration, a mild renal pathology change. In addition, NSPAKO mice, even in absence of anti-dsDNA, showed mesangial electron dense-deposits with discrete effacement of foot processes.

**Conclusions** NSPA is expressed in both PTEC and polarized MDCK epithelial cells with a polarized distribution that precludes direct interaction with circulating anti-P antibodies, which might access to this target only after glomerular filtration. Circulating anti-P can associate with mild kidney damage independently of NSPA expression, at least in non-lupus prone mice.

**Acknowledgements** CONICYT Basal grant PB12/2007 and FONDECYT Grant 1160513.

**AA-04** AUTOANTIBODIES TO M-PHASE PHOSPHOPROTEIN I (MPP-1: KIF20B) IN SYSTEMIC LUPUS ERYTHEMATOSUS

1May Y Choi1, 2Eric Campbell, 1Ann Clarke, 1Michelle Jung, 1Claire Barber, 2Yvan St Pierre, 1Marvin J Fritzler. 1Mayo Clinic, 2Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada; 2Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada

**Background** M-phase phosphoprotein (MPP-1), also termed kinesin interacting protein (KIF20B), is a 210 kDa protein that is highly expressed during cell division. Autoantibodies to MPP-1 were first described in approximately 25% of patients with systemic lupus erythematosus (SLE) and anti-ribosomal P (anti-P) antibodies may present lupus psychosis, cognitive impairment and lupus nephritis (LN). Our group provided a molecular mechanism to explain the neuronal alterations in SLE identifying the neuronal-surface P-antigen (NSPA) as an anti-P target involved in the regulation of synaptic glutamatergic transmission (Bravo-Zehnder et al. *A and R* 2015; Segovia-Miranda et al. *A and R* 2015). There is evidence suggesting that anti-P- and anti-dsDNA antibodies have the potential to perturb the function of renal cells in addition to complement activation. The mechanism of anti-P association with lupus nephritis remains unclear. It is possible that direct anti-P interaction with cell surface components activates intracellular signalling pathways resulting in renal cell damage. As a first approximation to this hypothesis we study whether and where NSPA is expressed in the kidney.

**Methods** NSPA expression was assessed by RT-PCR, immunoblot and anti-NSPA immunohistochemistry in C57WT mice, β-galactosidase (β-gal) histochemistry staining in transgenic mice bearing a LacZ gene under the promoter of NSPA gene and anti-P staining in the surface of primary cultures of PTEC and the human kidney cell line HK2. NSPA polarized distribution was studied in Madin-Darby canine kidney (MDCK) cells transfected with NSPA-GFP expression plasmid. The pathogenic potential of anti-P antibodies was analyzed by immunizing C57WT and NSPAKO mice with recombinant P0 ribosomal bearing (P0*) or not the P epitope (P0*) and testing anti-P and anti-dsDNA presence, proteinuria and renal pathology by histochemistry and electron microscopy.

**Results** NSPA is expressed in PTEC cells and display a mainly apical distribution in *vivo* and in *vitro*, including the transfected MDCK cells. Both P0* and P0* generated high levels of anti-P antibodies and some mice also developed anti-dsDNA antibodies. Mice presented mild proteinuria at 6 months of immunization. C57WT and NSPAKO mice immunized with either P0* or P0* also displayed perivenular lymphocytic infiltration, a mild renal pathology change. In addition, NSPAKO mice, even in absence of anti-dsDNA, showed mesangial electron dense-deposits with discrete effacement of foot processes.

**Conclusions** NSPA is expressed in both PTEC and polarized MDCK epithelial cells with a polarized distribution that precludes direct interaction with circulating anti-P antibodies, which might access to this target only after glomerular filtration. Circulating anti-P can associate with mild kidney damage independently of NSPA expression, at least in non-lupus prone mice.

**Acknowledgements** CONICYT Basal grant PB12/2007 and FONDECYT Grant 1160513.